Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-205-5p
- Development stage
- Preclinical
- Lead developer
- Hospital de Amor
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
anti-miR-205-5p is a synthetic antisense oligonucleotide designed to specifically target and neutralize microRNA-205-5p (miR-205-5p). In various malignancies, including cervical cancer, miR-205-5p functions as an oncomiR, promoting tumor progression by driving cell proliferation, migration, and invasion while suppressing apoptosis. By binding to the mature miR-205-5p sequence, the inhibitor restores the expression of downstream target genes such as FXYD6, MGP, and MMRN2. Research indicates that while anti-miR-205-5p may have limited pro-apoptotic activity as a monotherapy, it significantly enhances the sensitivity of cancer cells to chemotherapeutic agents like cisplatin, leading to increased late apoptosis. This suggests its potential utility as a combination therapy to overcome chemoresistance in cervical cancer and other miR-205-5p-overexpressing tumors.
- Other names
- miR-205-5p inhibitormiR205-5p inhibitormiR 205-5p inhibitorantagomir-205-5pantagomir205-5pantagomir 205-5pantagomiR-205antagomiR205antagomiR 205
Beyond the preview
Go deeper on anti-miR-205-5p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-205-5p.